# Syntrix Pharmaceuticals

Source: https://onco.cc/companies/syntrix-pharmaceuticals/  
OnCo record `syntrix-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Syntrix Pharmaceuticals, near Seattle, develops SX-682, a tablet that blocks signals tumours use to gather immune-suppressing cells around themselves. It is in phase 2 trials, including in prostate cancer.

## Summary

Syntrix Pharmaceuticals (Syntrix Biosystems, Inc.) of Auburn, Washington, develops SX-682, a small-molecule dual inhibitor of the chemokine receptors CXCR1 and CXCR2, which the company describes as inactivating immunosuppressive myeloid cells in the tumour microenvironment; it also has a pain programme. SX-682 is in phase 1 and phase 2 trials, among them NCT06228053, a Syntrix-sponsored phase 2 trial with enzalutamide in metastatic castration-resistant prostate cancer. Two 2026 National Cancer Institute SBIR awards fund a dose-expansion study of SX-682 alone and with decitabine in myelodysplastic syndromes and a phase 2 study with nivolumab and relatlimab in melanoma.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Syntrix Biosystems, Inc.; Syntrix Biosystems
- HQ: Auburn, WA
- Type: biotech
- Website: https://syntrixbio.com/

## Notes

- Company website (home and immuno-oncology pages) and the NIH RePORTER records read on 4 November 2026. The website says SX-682 is the only oncology therapeutic in development that blocks all parts of the CXCR1/2 axis; that is the company's claim.

## Sources

- Official website: https://syntrixbio.com/
- Immuno-oncology: SX-682: https://syntrixbio.com/pages/immuno-oncology/
- NIH RePORTER: award 5R44CA291622-03: https://reporter.nih.gov/project-details/11324659
- NIH RePORTER: award 1R44CA306688-01A1: https://reporter.nih.gov/project-details/11406776

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [SX-682](https://onco.cc/drugs/sx-682/)
- trials: [Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer](https://onco.cc/trials/nct06228053/)

---
JSON: https://onco.cc/api/v1/entities/syntrix-pharmaceuticals.json